ReviewCNS drugs2012
Minocycline: therapeutic potential in psychiatry.
Review in CNS drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02907437 (Minocycline add-on Medication to Antipsychotics in the Treatment of Schizophrenia Patients), which is not on this map. Cited by 56 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Minocycline add-on Medication to Antipsychotics in the Treatment of Schizophrenia Patients: A Double- Blind Randomized Controlled Trial
Who cites it
56 citing papers in PubMed, 5 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- Predictors of successful anti-inflammatory drug trials in patients with schizophrenia: A meta-regression and critical commentary.Brain, behavior, and immunity · 2023Pooled it
- Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Efficacy and tolerability of minocycline in depressive patients with or without treatment-resistant: a meta-analysis of randomized controlled trials.Frontiers in psychiatry · 2023Pooled it
- Tetracycline use in treating osteoarthritis: a systematic review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Pooled it
- Minocycline for Depressive Symptoms: a Meta-Analysis of Randomized, Double-Blinded, Placebo-Controlled Trials.The Psychiatric quarterly · 2020Pooled it
- Effect of minocycline on changes in affective behaviors, cognitive function, and inflammation in breast cancer survivors undergoing chemotherapy: a pilot randomized controlled trial.Breast cancer research and treatment · 2024Trial
- Targeting neuroinflammation with minocycline in heavy drinkers.Psychopharmacology · 2019Trial
- Trial
- Golden window of intervention in PTSD: a synthesis of preclinical evidence.Psychopharmacology · 2026Review
- Microglia Sing the Prelude of Neuroinflammation-Associated Depression.Molecular neurobiology · 2025Review
- Guarding minds: a narrative review on how n-acetylcyteine and ketones could shield sensitive patients from antibiotic neurotoxicity.Frontiers in pharmacology · 2025Review
- A Proteogenomic Approach to Unveiling the Complex Biology of the Microbiome.International journal of molecular sciences · 2024Review
- Network-based drug repurposing for schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Between Dysbiosis, Maternal Immune Activation and Autism: Is There a Common Pathway?Nutrients · 2024Review
- Biomarkers of stress resilience: A review.Neuroscience applied · 2024Article
- Minocycline Acts as a Neuroprotective Agent Against Tramadol-Induced Neurodegeneration: Behavioral and Molecular Evidence.International journal of preventive medicine · 2024Article
- Breaking free from the inflammatory trap of depression: Regulating the interplay between immune activation and plasticity to foster mental health.Neuroscience applied · 2024Review
- Microglia-neuron interactions in schizophrenia.Frontiers in cellular neuroscience · 2024Review
- Microbiota-Gut-Brain Axis and Antidepressant Treatment.Current topics in behavioral neurosciences · 2024Review
- Adjunctive minocycline for major depressive disorder: A sub-study exploring peripheral immune-inflammatory markers and associated treatment response.Brain, behavior, & immunity - health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacological interventions to treat psychiatric illness have previously focused on modifying dysfunctional neurotransmitter systems to improve symptoms. However, imperfect understanding of the aetiology of these heterogeneous syndromes has been associated with poor treatment outcomes for many individuals. Growing evidence suggests that oxidative stress, inflammation, changes in glutamatergic pathways and neurotrophins play important roles in many psychiatric illnesses including mood disorders, schizophrenia and addiction. These novel insights into pathophysiology allow new treatment targets to be explored. Minocycline is an antibiotic that can modulate glutamate-induced excitotoxicity, and has antioxidant, anti-inflammatory and neuroprotective effects. Given that these mechanisms overlap with the newly understood pathophysiological pathways, minocycline has potential as an adjunctive treatment in psychiatry. To date there have been promising clinical indications that minocycline may be a useful treatment in psychiatry, albeit from small trials most of which were not placebo controlled. Case reports of individuals with schizophrenia, psychotic symptoms and bipolar depression have shown serendipitous benefits of minocycline treatment on psychiatric symptoms. Minocycline has been trialled in open-label or small randomized controlled trials in psychiatry. Results vary, with findings supporting use in schizophrenia, but showing less benefit for nicotine dependence and obsessive-compulsive disorder. Given the limited data from rigorous clinical trials, further research is required. However, taken together, the current evidence suggests minocycline may be a promising novel therapy in psychiatry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.